title: Distinct efficacy of pegylated-interferon α2a and α2b during treatment of essential thrombocythemia.
authors: Nicolas
authors: N
authors: Noel
authors: Jean-Marie
authors: JM
authors: Michot
authors: Caroline
authors: C
authors: Besson
authors: Cécile
authors: C
authors: Goujard
authors: Olivier
authors: O
authors: Lambotte
mesh_terms: D019943:Amino Acid Substitution; D000998:Antiviral Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D053614:Janus Kinase 2 / Q000235:genetics / Q000378:metabolism; D008875:Middle Aged; D020125:Mutation, Missense; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage; D013920:Thrombocythemia, Essential / Q000097:blood / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C507924:JAK2 protein, human; D053614:Janus Kinase 2; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a
references: Cytokine. 2011 Jan;53(1):52-9
references: 20943413
references: Cancer Chemother Pharmacol. 2003 Jan;51(1):81-6
references: 12497210
references: Hepatology. 2010 Apr;51(4):1176-84
references: 20187106
references: Blood. 2000 Sep 15;96(6):2093-9
references: 10979953
references: J Viral Hepat. 2012 Jan;19 Suppl 1:33-6
references: 22233411
references: J Clin Oncol. 2009 Nov 10;27(32):5418-24
references: 19826111